Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 4 1

Status

Withdrawn 2Completed 1

Sponsor Class

OTHER 5INDUSTRY 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Dermatologic 2Genitourinary 1Gastrointestinal 1Classical hematology 1

Conditions

Melanoma 2Pancreatic Neoplasms 1Lung Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Anorexia 1Anemia 1

Interventions

Carboplatin 272Paclitaxel 267Gemcitabine 244Bevacizumab 225Cisplatin 216pembrolizumab 213Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 99Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 80Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Ipilimumab 64Bortezomib 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Infliximab × Clear all
NCT06646016 2025-12-26

EPIC

Therakos LLC

Phase 2 Withdrawn
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02763761 2018-10-09

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

Bristol-Myers Squibb

Phase 2 Withdrawn
DermatologicGenitourinaryThoracic

Carcinoma, Renal Cell, Lung Neoplasms, Melanoma

NCT00060502 2011-05-17

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia

Centocor, Inc.

Phase 2 Completed
73 enrolled
Classical hematologyGastrointestinal

Anemia, Anorexia, Cachexia, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡